Text or WhatsApp Richard at (808) 600-9260
Lion crestHealthcareInvestmentBanking.com

The Healthcare Company Pitch Deck: Slide by Slide for Investors

A healthcare pitch deck that gets read runs about 15 core slides. It leads with the ask, payer mix and unit economics, and it shows the valuation math from enterprise value through to the investor's percentage. Everything else goes in the appendix.

The deck answers three questions in order. Why does this business earn money? Why does that money hold up under reimbursement and regulatory pressure? What does the investor's capital buy, and what does it get back?

Data as of November 20, 2026. Each market figure names its source and period where it appears. Every company figure on this page belongs to one hypothetical dermatology group and is labeled as such. All derived figures are our arithmetic, with assumptions stated beside them.

The 15-Slide Healthcare Deck: Order, Purpose and Failure Points

Use this order for a physician group, dental platform, ASC, home health agency, behavioral health operator or healthcare services company. Healthtech founders swap slide 5 for pricing and contract structure and add the reimbursement pathway slide covered below.

# Slide What it must prove Healthcare-specific content Common failure
1 Cover and thesis One sentence on what you do and why it wins Specialty, geography, sites, providers A mission statement instead of a thesis
2 Investment summary The ask, the instrument, the use Raise size, pre-money, structure, timeline Burying the ask on slide 14
3 Patient demand Volume exists and is growing Referral volume, wait times, visit growth National spending figures with no local data
4 Care model How care is delivered and billed Service lines, sites of care, provider types Clinical detail an investor cannot evaluate
5 Payer mix Revenue quality Collections by payer, top contracts, renewal dates Gross charges instead of collections
6 Unit economics Each unit earns money Revenue and EBITDA per site, per provider, per visit Blended numbers that hide weak sites
7 Traction and KPIs The trend is real 3 years of visits, collections per visit, days in A/R Cherry-picked months
8 Market and deal activity Capital and buyers are active in the segment Sector deal counts, buyer types Hype with no source
9 Competition and referrals Why patients and referrers choose you Referral concentration, local competitors "We have no competition"
10 Regulatory and structure Ownership is clean Entity chart, MSO, licensure, counsel review Omitting it entirely
11 Team Operators and clinicians who can scale Clinical leader, CFO, ops lead, retention Credentials with no operating results
12 Financials Historical and projected numbers tie 3 years actual, 3 years projected, add-backs Projections disconnected from unit economics
13 Valuation and terms The price is defensible Adjusted EBITDA, multiple, comps, EV-to-equity bridge, exit waterfall A number with no math behind it
14 Use of funds Every dollar maps to a milestone Sites, hires, acquisitions, working capital "General corporate purposes"
15 Liquidity path How the investor gets paid back Distributions, recap, sale to platform or strategic No exit at all

For most services businesses, slides 2, 5, 6 and 13 carry the deck. Build those four first and write the rest around them. Rendered examples of all four appear below. The healthcare data room checklist maps the same slides to the documents investors request next.

Slide Anatomy: Headline, Exhibit, Footnote

Every slide uses the same three-part layout. Investors read the headline, check the exhibit, then read the footnote to see whether the number holds.

Zone What goes there Rule
Headline The claim, written as a full sentence State a conclusion, not a topic. "Payer Mix" is a topic. "Commercial and Medicare Advantage grew to 71% of collections" is a claim
Exhibit One table or one chart Never both. Readable on a phone
Footnote Period, basis and source for every number Collections, not charges. Fiscal year named. System of record named. Hypothetical inputs flagged

A headline that states a conclusion lets the investor agree or disagree in five seconds. A headline that names a topic makes them do the work, and most will not.

Where the Weight Sits by Segment and by Investor

By segment

Segment Slide that carries the most weight Metrics to lead with
Physician group 5 and 6 Collections by payer, wRVUs and collections per provider FTE, provider retention
Dental 6 EBITDA per office, same-office growth, hygiene share of production, PPO vs fee-for-service vs Medicaid mix
ASC 5 and 10 Case mix, cases per OR, out-of-network share, physician ownership and syndication structure
Home health 5 and 10 Medicare share, episodes and visits per clinician, star ratings, clinician turnover, licensure
Behavioral health 5 and 10 Payer mix, census and occupancy, length of stay, accreditation, survey history
Healthtech Reimbursement pathway and 13 Contracted revenue, gross margin, customer concentration, FDA status, billing codes and coverage

By investor type

Investor Reads first Wants proof of
PE platform buying add-ons Unit economics, payer mix Integration fit, normalized EBITDA, provider retention after close
Growth equity (healthtech) Revenue growth, gross margin, reimbursement path Contracted revenue, net retention, a coverage path that does not depend on one payer
Family office direct investor Investment summary, structure, liquidity path Governance rights, distribution policy, downside protection, alignment with the founder
Physician investor group Care model, referral structure An ownership structure counsel has reviewed, and distribution history

Anticipate the Objection on the Slide It Belongs To

Each slide should answer the question an investor would otherwise raise in the first meeting. Write the answer in before they ask.

Investor objection Slide that answers it Evidence that settles it
"One payer can reprice you." 5 Largest payer share, renewal date, rate history, dollar impact of a cut
"Your new sites will not ramp like your old ones." 6 and 14 Ramp curve from your own newest sites, months to breakeven
"Your providers leave after the deal." 11 Tenure, retention, compensation model, equity or rollover plan
"Your EBITDA is mostly add-backs." 12 and 13 Each add-back with its document, and the price without it
"Your multiple is made up." 13 Named private comps for your specialty and size band, plus a sensitivity table
"What do I get if this goes sideways?" 13 Exit waterfall showing the preference at low, middle and high outcomes
"There is no buyer for this." 8 and 15 Deal counts in your subsector, named buyer types
"The structure will not survive diligence." 10 Entity chart, management fee basis, counsel's review completed

Deck, Teaser, Appendix: What Goes Where

Healthcare founders overshoot because clinical detail feels like proof. It is not. The main deck carries the argument. The appendix and data room carry the evidence.

Document Length Purpose When it goes out
Teaser 1 to 2 pages Earn the first call First contact
Main deck About 15 slides Earn the meeting and the term sheet discussion After the first call
Appendix As long as needed Payer contracts summary, provider roster, licensure, quality metrics, site detail With the deck or on request
Data room Full documentation Support diligence and the quality of earnings review After interest is confirmed

Organize the data room the way the healthcare data room checklist lays out, and keep every figure in the deck identical to the figure in the data room.

Rendered Example Slides (Hypothetical Dermatology Group)

The slides below show the specificity investors expect. The company is a hypothetical five-site dermatology group, and every figure is illustrative. The same company runs through the valuation, waterfall and use-of-funds examples later on the page, so the numbers tie across slides. Provider FTEs count physicians and advanced practice providers (physician assistants and nurse practitioners), each full-time clinician as 1.0.


SLIDE 2 · Investment Summary

Headline: $10.0M of primary growth equity at a $31.0M pre-money equity value ($33.0M enterprise value) funds four new sites and two add-on acquisitions.

Item Content
Raise $10.0M minority growth equity, primary capital only
Instrument Convertible preferred, 1x non-participating liquidation preference
Pre-money $33.0M enterprise value, less $2.0M net debt, equals $31.0M equity value
Investor ownership 24.4% as converted
Use 4 de novo sites, 2 add-on acquisitions, working capital
Timeline Term sheet in Q1, close in Q2, after any regulatory review counsel identifies
Liquidity path Recap or sale to a dermatology platform in years 4 to 6

Footnote: Pre-money uses FY2025 adjusted EBITDA of $3.3M at a hypothetical 10.0x multiple. See slide 13 for the bridge and the source a real deck would cite.


SLIDE 5 · Payer Mix

Headline: Commercial and Medicare Advantage grew from 66% to 71% of collections over three years. No single payer exceeds 21%.

Payer class FY2023 FY2024 FY2025
Commercial 52% 54% 55%
Medicare Advantage 14% 15% 16%
Traditional Medicare 18% 17% 16%
Medicaid 10% 9% 9%
Self-pay and cosmetic 6% 5% 4%
Total 100% 100% 100%

Footnote: Percent of net collections, fiscal years. Source: practice management system, reconciled to reviewed financials. Largest payer, Commercial Payer A, 21% of FY2025 collections, contract renews July 2027. No out-of-network revenue.


SLIDE 6 · Unit Economics

Headline: Every site is EBITDA-positive. Provider productivity is flat across sites, and margin rises with site age from 10% to 28%.

Site Collections Site-level EBITDA Margin Provider FTEs Collections per provider FTE
Site A (opened 2016) $4.6M $1.29M 28% 5.0 $0.92M
Site B (opened 2018) $4.1M $1.07M 26% 4.5 $0.91M
Site C (opened 2019) $3.8M $0.91M 24% 4.0 $0.95M
Site D (opened 2021) $3.2M $0.64M 20% 3.5 $0.91M
Site E (opened 2024) $2.3M $0.23M 10% 2.5 $0.92M
Total $18.0M $4.14M 23% 19.5 $0.92M

Footnote: FY2025. Site-level EBITDA before corporate overhead. Provider FTEs include physicians and advanced practice providers. Collections per FTE is collections divided by FTEs.


The last column carries the argument. Each provider at Site E collects about what a provider at Site A collects (our arithmetic: $2.3M ÷ 2.5 = $0.92M and $4.6M ÷ 5.0 = $0.92M). The margin gap comes from fixed site costs spread over fewer providers, not from weaker clinicians. That is the evidence a de novo plan needs, and it comes from the company's own sites.

Site-level EBITDA is before corporate overhead. Company-level reported EBITDA on slide 13 ($2.6M) is after it, which implies $1.54M of corporate overhead (our arithmetic: $4.14M less $2.6M). Label which figure each slide shows. Investors catch the difference, and a deck that blurs it loses the argument on slide 13.

Slides 5 and 6: Payer Mix and Unit Economics Investors Rebuild

A generalist investor reads a P&L. A healthcare investor reads the payer mix behind it. Show both slides with three years of history.

Payer mix slide checklist

Unit economics slide checklist

Worked example: putting a dollar figure on payer concentration (hypothetical, our arithmetic)

Investors will ask what happens if the largest payer cuts rates at renewal. Answer it on slide 5 with numbers.

Line Amount
FY2025 collections $18.0M
Commercial Payer A share 21%
Commercial Payer A collections $3.78M ($18.0M × 21%)
Rate cut tested at renewal 5%
Collections lost $0.19M ($3.78M × 5%)
Adjusted EBITDA before the cut $3.3M
Adjusted EBITDA after the cut $3.11M
EBITDA reduction 5.7%
Enterprise value impact at the hypothetical 10.0x $1.9M

This is a deliberately severe case. It assumes every lost dollar of collections falls straight to EBITDA because provider pay and site costs do not flex with the rate. A practice that pays providers on a percentage of collections would recover part of the loss through lower compensation, so show that offset if it applies. A founder who presents this table with the renewal plan has turned the investor's biggest question into a sized, managed risk.

Weak sites in a ranked table build trust. A blended average that hides them gets found in the quality of earnings review and costs more there. The QoE prep checklist shows which adjustments survive that review.

Healthtech Variant: The Reimbursement Pathway Slide

A healthtech company that depends on a provider billing for its product needs a slide that answers four questions. Is the product regulated as a device? Which code does someone bill? Who covers it? Who pays the company?

Element What to show Common failure
FDA status Cleared, approved, pending or outside the device definition, with the pathway named Calling the product "FDA compliant" with no pathway named
Billing codes The CPT or HCPCS codes used, the code year and the code category Treating the existence of a code as a payment source. A code describes a service. Coverage and payment are separate decisions
Medicare coverage National or local coverage policy, or none Assuming a code means coverage or a set payment rate
Commercial coverage Which of the top payers in your markets cover it, with policy names and dates Counting one pilot as payer adoption
Revenue model Who pays the company: the practice, the payer, an employer or a health system Showing the provider's reimbursement as the company's revenue

Example (hypothetical): remote patient monitoring company

Item Slide content
FDA Connected blood pressure cuff, cleared
Codes billed by the practice Remote physiologic monitoring codes for setup, device supply and data transmission, and treatment management time, listed by code number from the CY2026 Medicare physician fee schedule
Medicare Billed by the enrolled practice under the physician fee schedule, subject to that year's code requirements
Commercial Covered under published policies at 4 of the top 6 payers in the company's markets, policy names and effective dates in the appendix
Company revenue Per-patient-per-month fee paid by the practice, 3-year contracts, 82% gross margin

Monitoring codes change with the annual fee schedule, so date the code list on the slide and update it each cycle. The investor's real question is concentration of reimbursement risk. If one code or one payer policy changes, how much revenue moves? Answer it with a percentage, the same way the dermatology group sized its Payer A exposure.

Slide 8: Market Data That Shows Buyer Depth, Not TAM

Healthcare investors do not need a national spending figure. They need evidence that capital and buyers are active in your segment, because that sets the liquidity path on slide 15. Keep each dataset in its own table and label its population. Deal counts from different trackers measure different things and should never be added or compared directly.

Private equity activity, calendar 2025 (PESP)

The Private Equity Stakeholder Project's 2025 healthcare deal review counted 1,029 private equity-backed healthcare deals in calendar 2025: 151 leveraged buyouts, 664 add-on acquisitions and 214 growth investments, involving 420 platform companies and 708 investment firms. PESP drew the data from PitchBook and LevinPro HC and states the count is likely an underestimate. The subsector counts below come from the same review and include all three deal types.

Subsector (PESP, calendar 2025) PE deals What it tells a founder
Health IT 151 Most active subsector in PESP's count. Growth equity is available
Dental care 149 95% were add-ons by PE-owned platforms. 10 of the 18 platforms with the most deals were dental
Outpatient care 148 Deep platform buyer pool
Medtech 117 Strategic and PE interest
Behavioral health 56 Active, with closer regulatory scrutiny

Inside outpatient care, Becker's ASC Review, reporting PESP's 2025 data, breaks down the same 148 deals. 119 were add-ons. Dermatology led with 24 transactions, eye care had 22 and oncology had 9. The hypothetical dermatology group would cite those 24 deals on slide 8 and name a sale to a dermatology platform as its liquidity path on slide 15.

Hospital and health system activity, 2026 (Kaufman Hall)

Use this only if your buyer, partner or customer is a hospital system. It counts hospital and health system transactions, a different population from the PESP data.

Measure Figure Source and period
Transactions announced, Q3 2026 16, matching Q3 2025 Kaufman Hall Q3 2026 M&A Quarterly Activity Report release, October 13, 2026
Total transacted revenue, Q3 2026 $8.2 billion Same release
Average seller size, Q3 2026 Approached $586 million in annual revenue Same release
Megamergers, Q3 2026 2, the third straight quarter with megamergers. Kaufman Hall counts a megamerger when the smaller party has more than $1 billion in annual revenue Same release
Buyer and deal type, Q3 2026 Not-for-profits were most acquirers. Divestitures were nearly one-third of announced deals Same release
Announced, January 1 to September 30, 2026 56 (22 in Q1, 18 in Q2, 16 in Q3), versus 46 in all of 2025, the lowest annual count since Kaufman Hall began tracking in 2011 Becker's Hospital Review, reporting Kaufman Hall counts

The same Kaufman Hall release reports hospital operating performance through August 2026: a 2.5% year-to-date operating margin including allocations, nearly 43% of hospitals operating at a loss, and non-labor expense per adjusted discharge up 6% over 2025, with supply expense up 5% and drug expense up 6%. A services company that sells cost reduction or outsourced capacity to hospitals can cite those figures on slide 3 as its demand case.

Match the data to the exit. A dental founder whose likely exit is an add-on sale should say so on slide 15 and name the platform buyer type. A healthtech founder should show growth-stage comparables, not buyout math.

Slide 13: Valuation, Terms and the Exit Waterfall

The valuation slide fails when the investor cannot rebuild the number. Show reported EBITDA, each add-back, the multiple, the source of that multiple and the bridge from enterprise value to equity value. The multiple prices the whole business. The investor buys equity, so net debt comes off before ownership is calculated.

Public multiples set a ceiling, not a price

Aswath Damodaran's NYU Stern EV/EBITDA data as of January 2026 covers US publicly traded companies only:

Damodaran sector (US public companies, January 2026) EV/EBITDA
Healthcare information and technology 21.27x
Healthcare products 19.78x
Drugs (biotechnology) 15.78x
Drugs (pharmaceutical) 15.25x
Healthcare support services 11.17x
Hospitals and healthcare facilities 8.86x
Total US market, excluding financials 16.95x

A single-specialty group with $3 million of EBITDA lacks public-company scale and liquidity. Price it off private transactions in your specialty and EBITDA size band, and name the source on the slide.

Where to get private comps, and how to cite them

Source What it gives you Limit How to show it on the slide
Banker or adviser comp set Closed-deal multiples by specialty and size Usually confidential A range with the source named and the number of deals
Deal databases (PitchBook, LevinPro HC) Announced deals and buyer names, some disclosed terms Many smaller practice deals close without disclosed price Only deals with disclosed terms, each dated
Written indications you have received What buyers will pay for your business Only counts if in writing "Two written indications in 2026," range only
Quality of earnings report The normalized EBITDA the multiple applies to Does not supply a multiple Footnote the QoE provider and date
Public comps (table above) Ceiling and direction Scale and liquidity gap Footnote only, never the headline multiple

The valuation multiples guide breaks private ranges out by segment. See the healthcare multiples by segment and size chart.


SLIDE 13 · Valuation and Terms (hypothetical)

Headline: At 10.0x adjusted EBITDA of $3.3M, the $10.0M raise buys 24.4% of the company on an as-converted basis.

Line Amount
Collections, FY2025 $18.0M
Reported EBITDA (after corporate overhead) $2.6M
Add-back: owner compensation normalized to market +$0.5M
Add-back: one-time EHR migration +$0.2M
Adjusted EBITDA $3.3M
Multiple (hypothetical) 10.0x
Pre-money enterprise value $33.0M
Less net debt (term loan less cash) ($2.0M)
Pre-money equity value $31.0M
New equity (primary, all to the balance sheet) $10.0M
Post-money equity value $41.0M
Investor ownership, as converted 24.4% ($10.0M ÷ $41.0M)

Footnote: The 10.0x multiple is an assumption chosen to show the arithmetic. It is not a market benchmark for dermatology. A real slide replaces it with private comps for the specialty and size band and names the source. Assumes no secondary sale, no option pool expansion and transaction expenses paid outside the raise. Add-back documentation in data room folder 4.


If a secondary sale, option pool expansion or transaction expenses apply, show each as its own line in the bridge.

Sensitivity to the multiple (our arithmetic, same $3.3M adjusted EBITDA, $2.0M net debt and $10.0M raise)

Multiple Pre-money EV Pre-money equity Post-money equity Investor ownership
8.0x $26.4M $24.4M $34.4M 29.1%
9.0x $29.7M $27.7M $37.7M 26.5%
10.0x $33.0M $31.0M $41.0M 24.4%
11.0x $36.3M $34.3M $44.3M 22.6%
12.0x $39.6M $37.6M $47.6M 21.0%

Each turn of multiple moves pre-money equity value by $3.3M and moves the investor's stake by 1.6 to 2.5 points across this range. The source of the multiple will be challenged harder than its level, so cite it.

Stress the add-backs the way an investor will (our arithmetic)

Line As presented EHR add-back rejected
Adjusted EBITDA $3.3M $3.1M
Pre-money EV at 10.0x $33.0M $31.0M
Less net debt ($2.0M) ($2.0M)
Pre-money equity value $31.0M $29.0M
Post-money equity value $41.0M $39.0M
Investor ownership for $10.0M 24.39% 25.64%

Rejecting one $0.2M add-back costs the founders $2.0M of pre-money equity value at 10.0x and hands the investor 1.25 more points of the company for the same check. Put only add-backs on the slide that you can document.

What the liquidation preference does at exit (hypothetical, our arithmetic)

Ownership of 24.4% describes the upside. The 1x non-participating preference on slide 2 governs the downside. At exit the investor takes the greater of its $10.0M back or 24.4% of equity proceeds. The crossover is the $41.0M post-money equity value.

Exit equity value Investor choice Investor receives Investor share of proceeds Founders and common receive Investor multiple on $10.0M
$25.0M Take preference $10.0M 40.0% $15.0M 1.0x
$41.0M Either (indifferent) $10.0M 24.4% $31.0M 1.0x
$80.0M Convert $19.5M 24.4% $60.5M 1.95x

Assumptions: exit equity value is after debt and transaction costs, no accrued dividends, no other preferred classes and no change in share count after the raise. A participating preference, a multiple above 1x or an accruing dividend would raise the investor's take in every row, so model each term the investor proposes before you sign. A family office investor will read this table before the ownership line, because it shows exactly how much protection the instrument provides.

Choosing the instrument

State the instrument on slide 2 and again on slide 13. Each sits at a different place in the capital stack and costs the founder something different.

Instrument Position What the founder gives up Fits when
Common equity Last in line Pro rata ownership and negotiated governance rights Investor wants full alignment and a long hold
Convertible preferred Ahead of common Downside priority through the preference, plus protective provisions A priced growth round with a minority investor
Convertible note Debt until it converts Valuation set later, usually with a discount or cap A bridge to a priced round within a defined window
Senior or subordinated debt Ahead of all equity Interest cost, covenants and personal or asset guarantees Stable EBITDA and acquisitions with predictable payback

See the healthcare capital stack chart.

Slide 14: Use of Funds Tied to Your Own Site Data

Use of funds (hypothetical)

Use Amount Milestone
4 de novo sites at $1.5M each $6.0M Open by month 18
2 add-on practice acquisitions $3.0M Close by month 12
Working capital $1.0M Funds new-site ramp losses
Total $10.0M

Tie the use of funds to slide 6. The company already has two data points for how a new site performs: Site E in its first full year and Site D after about four years open. Use those, not a generic industry ramp, and show the full cost, including the corporate overhead that more sites require.

De novo program economics (hypothetical, our arithmetic)

Line Site E benchmark (first full year) Site D benchmark (about four years open)
Build cost, 4 sites at $1.5M $6.0M $6.0M
Ramp losses to breakeven, 4 sites at $0.25M (the $1.0M working capital line) $1.0M $1.0M
Total capital at risk $7.0M $7.0M
Collections per site $2.3M $3.2M
Site-level EBITDA margin 10% 20%
Site-level EBITDA, 4 sites $0.92M ($2.3M × 10% × 4) $2.56M ($3.2M × 20% × 4)
Added corporate overhead (assumed) ($0.30M) ($0.30M)
EBITDA contribution after overhead $0.62M $2.26M
Implied value at the hypothetical 10.0x $6.2M $22.6M
Implied value less capital at risk ($0.8M) $15.6M

Assumptions: each new site performs like the existing site at the same age, the program adds $0.30M of regional management and billing cost (a hypothetical input), and value is undiscounted. At the Site E benchmark the program is worth less than it costs. At the Site D benchmark it creates $15.6M of implied value, but only after about four years and only if every site matures on schedule. That is the honest pitch: the de novo plan is a four-year bet on the ramp curve the company has already proven twice. An investor will haircut both columns. Showing the inputs lets them do it with your numbers rather than theirs.

Slide 10: The Regulatory and Ownership Structure Slide

Most founder decks skip this slide. Healthcare investors read it closely, because a structure problem can stop a deal or push the close date.

What the slide must show

The questions behind this slide belong with your own attorney. Use the healthcare compliance due diligence guide, the MSO guide and the healthcare M&A process guide to frame them, and settle any pre-close review question before you put a close date on slide 2.

Building Slide 10 for the Dermatology Group: Sample Slide and Document Map

The structure slide is the easiest one to get wrong by being vague. Here is how the hypothetical dermatology group would fill it in, followed by the documents that need to sit behind each line before the deck goes out.


SLIDE 10 · Regulatory and Structure (hypothetical)

Headline: Physicians own the clinical entity, the investor buys into the MSO, and counsel completed its structure review before the raise opened.

Item Content
Entity chart Physician-owned professional corporation operating all 5 sites, a management services agreement with the MSO, and the investor holding convertible preferred in the MSO holding company
Management fee Fixed annual fee supported by a third-party fair market value report, reset each year
Referral relationships Top 10 referral sources by volume listed in the appendix. No referring physicians hold equity
Licensure and accreditation All 19.5 provider FTEs licensed and credentialed with every contracted payer, roster in the appendix
Payer audits One commercial payer audit closed in 2024 with no repayment. None open
Pre-close review Counsel's assessment of any notice or review the raise triggers, and its effect on the Q2 close
Counsel review Healthcare regulatory counsel review completed Q4 2025, summary memo in data room folder 7

Footnote: Structure as of the deck date. Counsel and FMV provider named in the data room. Any change to the entity chart before close is disclosed to every recipient.


Document map: what sits behind each line of slide 10

Slide line Document in the data room Who prepares it Have it ready by
Entity chart Org chart with ownership percentages, formation documents for each entity Company counsel and CFO Before the first meeting
Management fee Management services agreement, current FMV report, three years of fees actually paid CFO with the valuation firm Before the first meeting
Referral relationships Referral volume by source, list of any financial relationship with a referral source Operations lead Before the first meeting
Licensure and accreditation Provider roster with license and credentialing dates, accreditation certificates Credentialing manager With the appendix
Payer audits Audit log with dates, findings and repayments for the past five years Revenue cycle lead With the appendix
Pre-close review Counsel's written view on timing, including a best-case and slow-case close date Company counsel Before slide 2 shows a close date
Counsel review Summary memo, or a letter confirming the review and its date Company counsel Before the deck goes out

How a slipped close flows through the rest of the deck (hypothetical, our arithmetic)

If counsel's slow-case close lands a quarter late, the add-on acquisitions on slide 14 move with it. Each add-on was budgeted at $1.5M of the $3.0M line. At the hypothetical 10.0x, $1.5M buys about $0.15M of EBITDA, so two add-ons a quarter late defer roughly $0.075M of EBITDA contribution (our arithmetic: $0.30M of combined annual EBITDA × one quarter). That is small against $3.3M of adjusted EBITDA, which is the point to make on the slide. Show the slow-case date on slide 2 as a range rather than a single quarter, and the investor reads the structure review as managed rather than open-ended.

Who Can See the Deck: Distribution Discipline

How the deck may be shared, and with whom, is a securities question. Read the capital raising guide and take those questions to your own attorney before the first email goes out.

If any investor is also a physician who refers patients to the company, the guide to raising capital from physician investors covers the issues to raise with counsel. Before agreeing to pay anyone for introductions to investors, read how to choose a healthcare investment banker.

Distribution rules for the deck itself

Video, Five Review Passes and the Pre-Send Checklist

A two-minute video of the founder walking a clinic or explaining a treatment protocol shows the care model faster than slide 4 can. Get signed consent from any patient who appears and keep protected health information off screen. Link the video from the deck rather than embedding a large file.

Run the deck through five passes, each with one job:

  1. Story and slide order. Can a non-clinician explain the business after reading it?
  2. Numbers. Every figure ties to the financial statements and the data room. Site-level and company-level EBITDA are labeled. De novo assumptions match your own newest sites and include added overhead.
  3. Regulatory. Counsel reviews slide 10, the close timeline and any claim about outcomes, FDA status or reimbursement.
  4. Investor lens. Someone outside the company rebuilds the valuation, ownership percentage and exit waterfall from slide 13 alone.
  5. Cut. Remove every slide and sentence that does not change an investor's decision.

Pre-send checklist

The healthcare deal mistakes guide lists the errors that cost founders the most after the deck goes out. The capital raising guide covers which investor types fit which raise.

Questions Owners Ask

How many slides should a healthcare pitch deck have?

This guide uses 15 core slides. That leaves room for payer mix, unit economics and ownership structure without burying the ask. Put payer contracts, provider rosters, licensure lists and quality data in an appendix or the data room. A main deck with more than 20 slides usually means the founder has not decided what matters. Put the ask, the payer mix and the unit economics early so the investor reaches them before deciding whether to take a meeting.

Should a physician practice show payer mix in the pitch deck?

Yes. Payer mix drives revenue quality and reimbursement risk, and a healthcare investor will rebuild it in diligence either way. Show the percentage of collections by commercial, Medicare Advantage, traditional Medicare, Medicaid and self-pay for three years, plus the top five commercial contracts and when each renews. Size the largest payer's exposure in dollars. A practice that holds payer mix back until diligence loses credibility at the exact moment it needs it.

Can I post my healthcare pitch deck on my website or LinkedIn?

Ask your securities attorney before you do. Sharing a deck privately with known investors and posting it publicly can lead to different outcomes for how the raise is structured and who can invest. Settle the question before the first deck goes out, then keep a log of every recipient.

What valuation multiple should a healthcare deck use?

Use private-market transaction comparables for your specialty and EBITDA size, sourced from a banker's comp set, a deal database or written offers you have received. Public multiples set a ceiling. Damodaran's January 2026 data on US public companies puts healthcare support services at 11.17x EBITDA and healthcare information and technology at 21.27x. Those companies have scale and liquidity a practice-level business lacks. Show adjusted EBITDA, every add-back, the multiple, its source and the bridge from enterprise value to equity value so the investor can rebuild your number.

How does a liquidation preference change what founders receive at exit?

A 1x non-participating preference lets the investor take back its money first or convert and share pro rata, whichever pays more. In this guide's hypothetical, a $10.0M investment for 24.4% means the investor takes $10.0M at any exit equity value below $41.0M. At a $25.0M exit the investor receives 40% of proceeds, not 24.4%. Above $41.0M the investor converts and the preference stops mattering. Show this table on slide 13 so founders and investors agree on the downside before the term sheet.

Sources